Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2016

01-08-2016 | Introduction to Invited Review Articles

Biological imaging in clinical oncology—introduction

Author: Yasumasa Nishimura

Published in: International Journal of Clinical Oncology | Issue 4/2016

Login to get access

Excerpt

Advances in various imaging modalities have apparently improved the clinical outcome in oncology. Staging and treatment planning of cancer have mainly been based on computed tomography (CT) and magnetic resonance imaging (MRI). In addition to these anatomical imaging techniques, biological and functional imaging, including positron emission tomography (PET) and functional CT and MRI, have recently advanced. With the addition of PET or PET/CT to CT and MRI, the staging accuracy has improved by detecting nodal and distant metastases [1, 2]. Furthermore, clinical studies using PET/CT for treatment planning have been reported [3‐6]. It has been demonstrated that fused PET/CT images are useful to delineate gross tumor volume (GTV) [2, 3, 7]. …
Literature
1.
Rohde M, Dyrvig AK, Johansen J et al (2014) 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer 50:2271–2279CrossRefPubMed
2.
Xu G, Li J, Zuo X et al (2012) Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting distant malignancies in patients with head and neck cancer: a meta-analysis. Laryngoscope 122:1974–1978CrossRefPubMed
3.
Deantonio L, Beldì D, Gambaro G et al (2008) FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 18:3–29
4.
Wang D, Schultz CJ, Jursinic PA et al (2006) Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 65:143–151CrossRefPubMed
5.
Schwartz DL, Ford EC, Rajendran J et al (2005) FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 27:478–487CrossRefPubMed
6.
Vernon MR, Maheshwari M, Schultz CJ et al (2008) Clinical outcomes of patterns receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 70:678–684CrossRefPubMed
7.
Okubo M, Nishimura Y, Nakamatsu K et al (2010) Radiation treatment planning using positoron emission and computed tomography for lung and pharyngeal cancer: a multiple-threshhold method for [18F]fluoro-2-deoxyglucose activity. Int J Radiat Oncol Biol Phys 77:350–356CrossRefPubMed
8.
Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981–991CrossRefPubMed
9.
Kam MK, Leung SF, Zee B et al (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873–4879CrossRefPubMed
10.
Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239CrossRefPubMed
11.
Asquith JC, Watts ME, Patel K et al (1974) Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res 60:108–118CrossRefPubMed
12.
Chapman JD, Baer K, Lee J (1983) Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 43:1523–1528PubMed
13.
Koh WJ, Rasey JS, Evans ML et al (1991) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22:199–212CrossRef
14.
Zimny M, Gagel B, DiMartino E et al (2006) FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33:1426–1431CrossRefPubMed
15.
Tachibana I, Nishimura Y, Shibata T et al (2013) A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. J Radiat Res 54:1078–1084CrossRefPubMedPubMedCentral
16.
Hoeben BA, Bussink J, Troost EG et al (2013) Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol 52:1257–1271CrossRefPubMed
Metadata
Title
Biological imaging in clinical oncology—introduction
Author
Yasumasa Nishimura
Publication date
01-08-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0999-4

Other articles of this Issue 4/2016

International Journal of Clinical Oncology 4/2016 Go to the issue

Original Article

Colorectal cancer in young patients: is it a distinct clinical entity?

Original Article

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Original Article

Clinical outcomes of abnormal cervical cytology and human papillomavirus-related lesions in patients with organ transplantation: 11-year experience at a single institution

Original Article

Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan

Original Article

Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer

Original Article

Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits